Carlsmed Raises Funds to Support aprevo Spinal Devices

Carlsmed closed an oversubscribed $30 million Series B funding round, The company plans to use proceeds to ramp commercialization of aprevo®, Carlsmed’s FDA-cleared personalized surgical devices.

In 2020, the company closed a $10 million Series A financing to commercialize a digital + surgical planning solution and personalized aprevo...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us